Nathalie Engel

Title: Nathalie Engel: Innovator in Biosynthesis

Introduction

Nathalie Engel is a prominent inventor based in Rixheim, France. She has made significant contributions to the field of biosynthesis, particularly in the development of DNA fragments related to antibiotic production. With a total of 2 patents, her work has implications for both medicine and biotechnology.

Latest Patents

One of Nathalie Engel's latest patents focuses on the "Rifamycin biosynthesis gene cluster." This invention primarily relates to a DNA fragment that can be obtained from the gene cluster responsible for rifamycin biosynthesis within the genome. It comprises at least one gene or a part of a gene that codes for a polypeptide involved in the biosynthesis of rifamycin. The patent also includes a method for preparing this DNA fragment, as well as recombinant DNA molecules that incorporate it. Additionally, the invention covers plasmids and vectors derived from these DNA fragments, along with host organisms transformed with the plasmid or vector DNA.

Another significant patent by Engel is related to "Staurosporin biosynthesis gene clusters." This work further emphasizes her expertise in the field of biosynthesis and genetic engineering.

Career Highlights

Nathalie Engel is currently employed at Novartis AG, a leading global healthcare company. Her role at Novartis allows her to collaborate with other experts in the field and contribute to innovative research and development projects.

Collaborations

Throughout her career, Nathalie has worked alongside notable colleagues such as Thomas Schupp and Christiane Toupet. These collaborations have enriched her research and expanded the impact of her inventions.

Conclusion

Nathalie Engel's contributions to biosynthesis and genetic engineering are noteworthy, with her patents paving the way for advancements in antibiotic production. Her work at Novartis AG and collaborations with esteemed colleagues further highlight her influence in the field.